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Background: Good prognostic tools for predicting disease progression in early stage prostate cancer (PCa) are still
missing. Detection of molecular subtypes, for instance by using microarray gene technology, can give new
prognostic information which can assist personalized treatment planning. The detection of new subtypes with
validation across additional and larger patient cohorts is important for bringing a potential prognostic tool into the
clinic.
Methods: We used fresh frozen prostatectomy tissue of high molecular quality to further explore four molecular
subtype signatures of PCa based on Gene Set Enrichment Analysis (GSEA) of 15 selected gene sets published in a
previous study. For this analysis we used a statistical test of dependent correlations to compare reference signatures
to signatures in new normal and PCa samples, and also explore signatures within and between sample subgroups
in the new samples.
Results: An important finding was the consistent signatures observed for samples from the same patient
independent of Gleason score. This proves that the signatures are robust and can surpass a normally high tumor
heterogeneity within each patient. Our data did not distinguish between four different subtypes of PCa as
previously published, but rather highlighted two groups of samples which could be related to good and poor
prognosis based on survival data from the previous study.The poor prognosis group highlighted a set of samples
characterized by enrichment of ESC, ERG-fusion and MYC + rich signatures in patients diagnosed with low Gleason
score,. The other group consisted of PCa samples showing good prognosis as well as normal samples. Accounting
for sample composition (the amount of benign structures such as stroma and epithelial cells in addition to the
cancer component) was important to improve subtype assignments and should also be considered in future studies.
Conclusion: Our study validates a previous molecular subtyping of PCa in a new patient cohort, and identifies a
subgroup of PCa samples highly interesting for detecting high risk PCa at an early stage. The importance of taking
sample tissue composition into account when assigning subtype is emphasized.
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Identification of molecular alterations in prostate cancer
(PCa) using gene expression measurements enables sub-
typing of tumors which can identify molecular risk pro-
files and therefore improve clinical outcome. In addition
to relevant clinical parameters such as prostate specific
antigen (PSA) and Gleason score, knowledge about
relevant prognostic gene expression subtypes could
help in improving personalized treatment strategies
both in postoperative follow-up and in recruitment to
active surveillance.
Gene expression based subtypes of breast cancer asso-
ciated with significant differences in prognosis were
established more than 10 years ago [1]. Attempts have
been made to define subtypes in PCa in a similar man-
ner [2,3], but no robust subtypes have currently been
established. One reason may be the highly heteroge-
neous tissue composition in PCa tissue samples, where
the varying amounts of cancer and normal tissue (benign
epithelial and stromal cells) may have large impact on
gene expression levels in each sample [4]. In addition to
compositional variations, PCa is a highly heterogeneous
disease manifested by a large variability in molecular
tumor characteristics between different patients [5]. Also
the degree of genetic heterogeneity in multiple tumor
nodes within the same patient due to polyclonal com-
position remains an open question [6,7]. The identifica-
tion of molecular markers which characterize PCa at the
level of individual genes has so far been challenging
[8,9]. It has thus been suggested that the molecular vari-
ation underlying the observed differences of PCa, as well
as other cancers, does not manifest itself at the level of
individual gene expression, but rather at the level of bio-
logical pathways and modules of functionally related
genes, often represented as gene sets [10-12].
Markert et al. [3] recently investigated the heterogen-
eity in PCa by clustering sample signatures based on
Gene Set Enrichment Analysis (GSEA) from 15 pre-
selected gene sets to identify subtypes of PCa. The gene
sets for subtype assessment were all chosen due to their
association with cancer in general and PCa in particular
(see below). Using the signature, Markert et al. [3] iden-
tified five and four subtypes, respectively, in two differ-
ent patient cohorts; a watchful-waiting cohort from
Sweden [8] and a cohort subjected to radical prostatec-
tomy from Memorial Sloan-Kettering Cancer center
[13]. They related the different subtypes to patient sur-
vival, and identified two subtypes characterized by high
lethality and bad prognosis, as well as three (two) less
dangerous subtypes characterized by good prognosis.
One subtype was particularly aggressive showing high
scores for gene sets related to embryonic stem cell
(ESC) characteristics, proliferation, and PTEN mutation.
A gene set related to P53 mutation was also enriched inthis bad prognosis subtype in the watchful waiting co-
hort, but not in the other cohort. Another subtype was
moderately aggressive and characterized by high scores
for a gene set related to TMPRSS2-ERG fusion, a gene
fusion regularly found in PCa [14]. Markert et al. [3]
concluded that their five (four) subtypes could have clin-
ical implications in predicting adverse outcome for PCa
patients with low Gleason score. Today, low-risk PCa
patients (PSA <10-15 ng/ml, Gleason score <7 and
organ-confined cancer [15]) should be offered deferred
treatment (active surveillance) to minimize the risk of
overtreatment. However, due to the lack of good prog-
nostic models, a number of these patients will harbor a
more aggressive disease than expected and experience
poor survival if not referred to radical treatment. If the
results by Markert et al. [3] can be reproduced and in-
troduced to a clinical setting, decision making for inclu-
sion into active surveillance programs and postoperative
follow-up for patients with a poor genetic signature can
be facilitated.
Using fresh frozen radical prostatectomy prostate tis-
sue material [16], we have previously analyzed gene
expression profiles in 156 samples (116 PCa and 40 nor-
mal) from 41 patients using microarray technology [17].
All analyzed tissue samples were proven to be of high
molecular quality, and thorough histopathological evalu-
ation to characterize the composition of the relative
amounts of cancer and normal tissue was performed.
Several samples were taken from the same patient, enab-
ling the possibility to evaluate the intra-patient molecular
variability. In the current study, we used our previously
generated gene expression profiles to validate the PCa
subtypes introduced by Markert et al. [3]. Reasons for
mis-classifications and identification of molecular similar-
ities in samples from PCa patients with poor prognosis
and low Gleason score were especially considered. Fur-
thermore, the significance of sample composition (cancer
and normal tissue) on subtype classification was evaluated
and the persistency of the subtype classification in samples
with different Gleason score from the same patients was
assessed.
Gene signatures in prostate cancer
Tumors originating from a variety of tissues and organs
have shown properties characteristic of embryonic stem
cells (ESCs). These ESC characteristics are often associ-
ated with aggressiveness and poor prognosis, especially
in epithelial cancers like breast cancer [18,19]. The spe-
cial properties of stem cells, such as proliferation, differ-
entiation and self-renewal express a more malignant
phenotype. ESC characteristics are also typical for in-
duced pluripotent stem cells (iPSCs), where transcrip-
tion factors characteristic for ESCs are used to introduce
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of ESC genes are generally accompanied by a reduced ex-
pression of genes regulated by the polycomb repressive
complex (PRC). PRC regulation is particularly important
in ESCs, where polycomb repress so-called bivalent genes
which are either activated or repressed depending on the
further path of differentiation [21]. Early dysregulation by
the PRC complex in ESCs has been shown to result in a
phenotype where PRC-regulated genes are generally re-
pressed, and this is characteristic for poorly differentiated
cancers [22].
Another characteristic feature of aggressive cancers is
the activation of the MYC oncogene. MYC is a consti-
tutively expressed transcription factor with many tar-
gets in different contexts, and it was recently suggested
that its main function is to reinforce transcription of
already expressed genes [23,24]. A specific MYC mod-
ule active in ESCs was recently shown to be particularly
important for cancer development [25]. ESC, PRC and
MYC are all properties shared by tumors from several
types of cancer. The aberrant fusion between androgen
regulated genes, in particular TMRPSS2, and members
of the ETS family of transcription factors (most com-
monly ERG) is specific to PCa. TMRPSS2-ERG fusion
is present in about 50% of all PCa tumors [26]. Prostate
tumors positive for ERG-fusion are characterized by an
upregulation of targets for the transcription factor
ERG, which in turn may lead to upregulation of Poly-
comb genes, thus linking ERG-fusion to Polycomb re-
pression [27].
Mutations in the tumor suppressor genes P53 and
PTEN, together with the oncogene RAS are frequently
found in tumors. P53 and/or PTEN mutations are both
common in PCa, and have recently been shown to in-
crease proliferation [28]. However, the role of RAS muta-
tion in PCa is less clear [29,30]. Epithelial to Mesenchymal
Transition (EMT) is a general characteristic for high grade
metastatic tumors resulting in increased cell motility
and invasiveness [31]. This aggressive tumor property is
generally driven by the transformation of epithelial
tumor cells into mesenchymal tumor cells. Inflamma-
tion, on the other hand, affects tumors at all stages of
development, from initiation through cancer progres-
sion and metastasis, and is mainly regulated through
the production of tumor promoting cytokines, both in
the tumor and in the tumor microenvironment [32]. In
the prostate, inflammation manifests itself as Prolifera-
tive Inflammatory Atrophy (PIA) lesion which may both
precede tumor formation and infiltrate the tumor as it
develops [33]. Finally, normal and tumor neuroendo-
crine cells in the prostate have been shown to partici-
pate in the oncogenic processes in PCa progression, and
ultimately to the transformation of the tumor to an an-
drogen independent phenotype [34].Methods
Patients and PCa samples
All patients scheduled for radical prostatectomy at St.
Olav Hospital, Trondheim University Hospital are in-
vited to donate a 2 mm transversal tissue slice which is
collected and stored for relevant research projects in the
Regional Research Biobank of Central Norway. All sam-
ples for this study were extracted in frozen conditions by
a highly specialized harvesting method which is presented
and published by our research group [16]. By cutting
4 μm cryosections from the extracted cylinder tissue sam-
ples (mean weigh: 12.7 mg, 2 mm thick), histopathology,
including estimation of amount of stroma, benign epithe-
lium, cancer and Gleason grade was confirmed before any
of the analyses were initiated. Normal samples were taken
as far away from the tumor as possible on each tissue slice.
The selected samples were used for RNA extraction and
microarray analyses, obtaining transcriptomic data, de-
scribed in detail in a previous publication [17]. The study
is approved by the Regional Committee for Medical and
Health Research Ethics (REC), Central Norway, and the
Data Inspectorate of Norway. A set of microarray mea-
surements on PCa tissue samples used for validation
was downloaded from GEO accession GSE8218 [35,36].
Details of this datasets and validation results are given
in Additional file 1: Text S1.
Microarray analysis
A detailed description of the steps used for microarray
analysis to obtain gene expression levels are given in a
previous publication [17]. The microarray data are pub-
licly available in Array Express with accession number E-
MTAB-1041. Metadata consisting of sample composition
(cancer and healthy stromal/epithelial cells) and patient
number for each sample is found in Additional file 2.
Gene set enrichment analysis
We downloaded 21 gene sets related to prostate cancer
from Markert et al. [3]. A sufficient set of genes for all sig-
natures were present in our microarray data (Additional
file 1: Table S2, and Additional file 3), and Gene Set En-
richment Analysis (GSEA) [3,37] was performed for each
gene set in each of the 156 samples. Prior to GSEA, each
gene was mean-centered across all samples. In each sam-
ple, genes were then sorted in descending order according
to their normalized and mean-centered microarray ex-
pression values. Positive and negative GSEA scores were
then calculated for each gene set in each sample by the
following formulas:
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if gene j is not in signature GS, where N is the total
number of genes, and S is the number of genes in the
gene set. This produces one positive and one negative
score for each gene set in each sample. A total score is
calculated by subtracting the negative from the positive
score, resulting in one total gene set score for each of
the 21 gene sets in each sample. The number of gene set
scores was then reduced to 15 by averaging over scores
from related gene sets (Additional file 1: Table S2). For
normalization of gene set scores we tested three different
strategies: i) Normalization to zero-to-one scale across
each sample, ii) normalization to zero-to-one scale across
each gene set, and iii): normalization to p-values by re-
peated sampling of random gene sets [3]. The two former
normalizations showed similar performance, and both
performed better than the p-value normalization. We
chose to use normalization for each sample, because this
would mostly resemble a clinical setting where standard
gene sets are tested on new patients.
Correlation of sample signatures to previously identified
subtypes of prostate cancer
We visually translated the heatmap from Markert et al.
(Figure four B) based on samples from a radical prostatec-
tomy cohort from Memorial Sloan-Kettering Cancer cen-
ter to numeric values (Figure 1A). The four subtypes are
categorized into two subtypes with bad prognosis; one
characterized by enrichment for PTEN-, ESC and Prolifer-
ation signatures (BP-E/P/Pr), and one by specific enrich-
ment of the ERG-fusion gene set (BP-ERG), and two
subtypes with good prognosis (GP1 and GP2). The scores
were defined by a visual inspection of the heatmap, assign-
ing values between -1 and 1 manually according to the
color code. The four resulting subtype signatures were
correlated to the signatures calculated from our 156 sam-
ples using Pearson correlation. A sample was defined as
significantly belonging to one of the four subtypes, if the
signature correlation to this subtype was significantly bet-
ter compared to all other subtypes. For this analysis we
implemented a statistical test of dependent correlations
[38] for various p-value thresholds. In the second test, weinvestigated whether a sample was significantly better cor-
related to one of the two subtypes showing poor prognosis
(subtype 1 – BP-E/P/Pr and 2 – BP-ERG in Markert et al.)
than to the two subtypes showing good prognosis (subtype
3 – GP1 and 4 – GP2 in Markert et al.). To be assigned to
poor prognosis subtype, the correlation to either subtype
BP-E/P/Pr or BP-ERG must be significantly better than to
both subtype GP1 and GP2, but not necessarily signifi-
cantly different between subtypes BP-E/P/Pr and BP-ERG.
Accordingly, to the poor prognosis subtype, the correl-
ation to either subtype GP1 or GP2 must be significantly
better than to both subtype BP-E/P/Pr and BP-ERG, but
not necessarily between subtypes GP1 and GP2. For this
test we used the test of dependent correlations for differ-
ent p-value thresholds.
Calculation of within and between group signature
correlations
Within and between correlations were calculated for
each considered group. Within correlations of cancer
and normal samples are all possible correlations within
all cancer and normal samples respectively. For Gleason
score, within correlations are all correlations within can-
cer samples classified with the same Gleason score, and
between correlations are all correlations between cancer
samples with different Gleason score. For patients, within
correlations are correlations within all cancer samples from
the same patient, while between correlations are all corre-
lations between cancer samples from different patients.
For the comparison of normal tissue samples to PCa sam-
ples in the same versus different patients, within correla-
tions are all correlations between normal samples and
cancer samples in the same patients, while between corre-
lations are correlations between all normal samples and
cancer samples in different patients.
Subtraction for normal tissue component
To emphasize the cancer signature in each prostate cancer
sample, cancer samples were subtracted for their normal
tissue component. This was done by first calculating the
average normal signature based on the 40 normal samples
with no cancer tissue. Each of 116 cancer samples was
then subtracted for their normal component according
the content of normal tissue using the following equation:
PRcorrected ¼ PR− SEAVG
 frac
1−frac
Here PR is the original signature for an arbitrary sample,
SEAVG the average normal signature based on all normal
samples, and frac the fraction of normal tissue in the sam-
ple, ranging from 0.1 (very little) to 0.9 (almost entirely
consisting of normal tissue). A higher fraction value re-





Figure 1 Gene signatures are consistent within samples from the same patient, but are also affected by tissue composition within
each sample. A) Numerical assessment of signatures for four subtypes of prostate cancer based on the heatmap in Figure four(B) in Markert
et al. [3]. B) Assignment of PCa samples to subtypes with poor prognosis and subtypes with bad prognosis. The bars show number of samples
assigned to the good and bad prognosis subtypes at different p-value thresholds (0.05, 0.15, 0.25 and 0.5 from left to right). B-Top) At a p-value
threshold of 0.05 (0.25) 37 (52) out of 116 PCa samples are assigned with bad prognosis, and 10 (21) with good prognosis, while 31 (35) out of 40
normal samples are assigned with good prognosis. B-Middle) Sample assignment is strongly dependent on the relative amounts of cancer and
normal tissue in each sample. B-Bottom) PCa sample assignment did not depend on Gleason score, and samples are equally likely to be assigned
with poor and good prognosis regardless of Gleason score. C-Top) Signature correlations between PCa samples from the same patients are better
than signature correlations between samples with the same Gleason scores. This was also the case when samples from the same patient had
different Gleason scores. C-Bottom) Signature correlations within and between various sample groups. Normal samples are more similar to PCa
samples when taken from the same patient (Normal-PCa – Same patient) . D) Subtracting the average normal signature improves sample similarity
within patient and Glesaon grooups. E) Bad prognosis samples show elevated scores in MYC, ESC and ERG-fusion gene sets. The three samples
sets are: i: Bad prog) 54 PCa samples bad prognosis (cluster 1, Figure 2) ii: Good prog) 21 PCa samples initially assigned with good prognosis
(p<0.25, Table 1A) and iii: Normal) 40 normal samples.
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emphasized cancer signatures in the normal samples,
we subtracted the normal signature from these samples
as well using the strongest subtraction factor of 0.9.
Hierarchical clustering
Hierarchical clustering of the 116 cancer samples was per-
formed using the Hierarchical clustering (scipy.cluster.hierarchy) package in python, using correlation as dis-
tance measure. All other parameters were set to default
values. For the clustering, we used GSEA signatures
based on the 15 gene sets from Markert et al. after sub-
traction for the average normal signature. Samples and
signatures were sorted according to the leaves order
from the clustering in both the sample and the signa-
ture direction before plotting, so similar samples and
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gene sets were subjected to the same GSEA, normalization
and normal tissue subtraction as the original 15 gene sets.
Results
Validating the four recently published PCa subtypes in
fresh frozen radical prostatectomy tissue
Using the 15 gene sets from Markert et al. [3], we used
GSEA to calculate a gene set signature for each of our
tissue samples (116 PCa and 40 normal). We compared
these sample signatures to the four subtypes generated
from the cohort subjected to radical prostatectomy from
the Memorial Sloan-Kettering Cancer center (Figure 1A)
using a statistical test of dependent correlations [38]
(See Methods). In Markert et al. [3], two of the subtypes
(ESC/PTEN-/Proliferation – BP-E/P/Pr and TMPRSS2-
ERGfusion – BP-ERG) were associated with bad progno-
sis, and another two subtypes (Good Prognosis 1 - GP1
and Good Prognosis 2 - GP2) were associated with good
prognosis based on follow up data on survival time.
Only few samples (11 PCa and 9 normal at p < 0.05)
could be uniquely assigned to one of the four published
subtypes (Table 1A). However, a substantial number of
the samples (47 PCa and 31 normal, p < 0.05) could be
assigned to either the two signatures related to good
prognosis or the two signatures related to bad prognosis
(Table 1A). The normal tissue samples are exclusively
assigned to the subtypes with good prognosis. The PCa
samples were mostly assigned to the subtypes with bad
prognosis, but a few PCa samples also fell into the sub-
types for good prognosis. The general separation of PCa
and normal samples into bad and good prognosis categor-
ies, respectively, appeared to be robust, where normal
samples were assigned to the bad prognosis subtypes onlyTable 1 Number of samples assigned exclusively and significa
Steiger [38]) to one of the four PCa subtypes, compared to th
are combined into two categories with bad and good progno
A) Original signature
p-value threshold BP-E/P/Pr BP-ERG
PCa 0.05 10 0
0.25 22 3
Normal 0.05 0 0
0.25 0 0
B) Signatures subtracted for the average normal signature
p-value threshold BP-E/P/Pr BP-ERG
PCa 0.05 9 1
0.25 23 5
Normal 0.05 0 0
0.25 4 0
While only few samples could be assigned exclusively to one of the four subtypes,
combined categories of good and bad prognosis.at very high p-value thresholds (p > 0.5) (Figure 1B-Top).
Subtype assignments into of samples to good and bad
prognosis were also prevalent for samples in the additional
validation study, however, in this dataset contamination of
cancer signatures in normal samples was also present
(Additional file 1: Text S1).
Subtype assignment are strongly dependent on sample
composition, but independent of Gleason score
PCa tissue samples rarely contain pure cancerous tissue,
but usually consist of cancer and normal tissues (stromal
and epithelial cells) in various proportions. Thus, PCa
samples consisting of 50% cancer and 50% normal cells
will have gene expression levels resembling both cancer
and normal samples. The tissue composition of each
PCa sample is therefore likely to affect the assignments
to the two subtype categories of good and bad prognosis.
In our fresh frozen radical prostatectomy tissue, a sub-
stantial number of tissue samples could not be assigned
to the poor or good prognosis categories, even at high
p-value thresholds. When investigating the dependency
between tissue composition and the number of unassigned
samples, we observed a higher number of unassigned cases
where samples contained similar proportions of cancer
and normal tissue (proportions of 50/50, 60/40 and 40/60)
(Figure 1B-Middle). However, the dependency was not ab-
solute, because nine PCa samples with at least 80% cancer
tissue, and five normal samples (consisting of 100% benign
epithelial and stromal cells) remained unassigned (p < 0.25).
Additionally, 10 PCa samples assigned with a good prog-
nosis subtype (p < 0.05) contained high percentages of
normal tissue (58% on average, compared to 38% on aver-
age for all PCa samples), which may influence thently (p < 0.05 and p < 0.25, dependent correlations by
e number of samples assigned when the four categories
sis
GP1 GP2 Bad prognosis Good prognosis
0 1 37 10
2 11 52 21
2 7 0 31
4 17 0 35
GP1 GP2 Bad prognosis Good prognosis
0 1 53 4
0 4 73 7
0 6 3 12
2 13 7 19
a substantial number of samples could be assigned to one of the two
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score dependency on subtyping, we could not identify a
preference in sample assignment for any particular Glea-
son score (Figure 1B-Bottom). Samples with Gleason
score 8 or 9 were just as likely to be assigned with poor
prognosis as those with Gleason score 6 or 7. For the add-
itional validation data, the effect of normal tissue contam-
ination in cancer samples seemed to have less influence
on subtype assignment, and samples with low tumor con-
tent, as well as normal samples, could both be assigned to
the bad prognoses subtype (Additional file 1: Text S1).
Subtype assignments are homogenous within samples
from the same patient, but not necessarily between
patients having the same Gleason score
In our dataset, we had several cancer and normal samples
that were extracted from the same patient, giving us the
opportunity to investigate the genetic heterogeneity among
patients. In cancer samples, we observed high correlations
between signatures within each patient (median r = 0.56)
compared to correlations between patients (median
r = 0.09, p ≈ 0.0, Figure 1C). This is in contrast to the com-
parison of signature correlations within samples with the
same Gleason score (median r = 0.14), and samples with
different Gleason scores (median r = 0.08, p = 0.0001).
This indicates that signatures retain their within patient
homogeneity, despite having different Gleason scores. In
other words, two samples with different Gleason score
from the same patient are more likely to have correlated
gene signatures than two samples with the same Gleason
score taken from different patients. In addition, when con-
sidering only samples within the same patient, we found
no significant increase in the correlation of signatures for
samples with the same Gleason score compared to sam-
ples with different Gleason score (p = 0.75, Additional file 1:
Figure S3).
When comparing similarity using signature correla-
tions of cancer and normal samples in general, normal
samples were as expected more similar than cancer sam-
ples (median r = 0.10 and 0.55 for cancer and normal
respectively, p ≈ 0.0). Furthermore, the signatures for
normal and cancer samples taken from the same patient,
are more similar compared to signatures from normal
and cancer samples taken from different patients (median
r = -0.08 and r = -0.27 for same and different patients re-
spectively, p = 0.0006). This observation confirms the
dependency of signatures between PCa samples and their
surrounding normal tissue [39].
When considering the 21 PCa samples assigned with
good prognosis (p < 0.25), 18 of these samples are shared
between 12 patients, and only 3 of the other samples from
these 12 patients are assigned with poor prognosis. Thus,
the good prognosis PCa samples seem to be distributed ina subset of patients with a certain degree of similarity in sig-
natures. This observation supports the hypothesis that the
good prognosis PCa samples not only have higher levels of
normal tissue, but also represent a less aggressive subtype
of PCa. Moreover, PCa samples with Gleason score 6 and 7
taken from patients who also harbored samples with Glea-
son score 8 and 9, were either unclassified or assigned with
poor prognosis, also supporting this hypothesis.Subtraction of an average normal signature to emphasize
the cancer component in the heterogeneous tissue
improves subtype classification of PCa samples
We have shown that the heterogeneous tissue compos-
ition of PCa samples affects subtype assignments, espe-
cially when the proportions of cancer and normal tissue
are similar. To emphasize the molecular cancer compo-
nent in each sample, we used all normal samples to con-
struct an average normal signature based on the 15 gene
sets. The average normal signature was then subtracted
from the original signature for each cancer sample, where
the proportion of subtraction was relative to the normal
tissue component from the histopathological evaluation.
This procedure improved the subtype assignment for sev-
eral cancer samples. Specifically, the number of PCa sam-
ples assigned with bad prognosis increased from 37 to 53
(p < 0.05, at p < 0.25 this number increased from 52 to 73,
Table 1B). All samples assigned with poor prognosis after
subtraction were unassigned before subtraction. All sam-
ples initially assigned with poor prognosis retained their
assignment after subtraction. As expected, no new samples
were assigned with good prognosis due to the signature
similarity between cancer samples with good prognosis nor-
mal samples.
After subtraction of an average normal signature, within
patient correlations of signatures improved (median r =
0.70 compared to 0.55). This was also the case for samples
within the same Gleason score (median r = 0.37 compared
to 0.14) (Figure 1D). To investigate whether the subtrac-
tion procedure could over-emphasize cancer signatures in
normal samples, we applied the subtraction strategy to the
normal samples as well (composition subtraction factor of
0.9, the highest factor used for any sample in the study,
see Methods). All samples initially assigned with good
prognosis either retained their assignment, or changed to
unassigned (p < 0.05). We thus conclude that the subtraction
procedure improves the subtype classification of cancer sam-
ples, and does not over-emphasize cancer signatures in nor-
mal samples.
Subtraction of the same average normal signature in the
validation samples also improved subtype classification in
the additional validation dataset, however, for this dataset
enrichment of cancer signatures for some of the normal
samples was also observed. (Additional file 1: Text S1).
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ERG-fusion are characterized by low Gleason score but
potentially poor prognosis
To investigate how our dataset of PCa samples clustered
based on signatures subtracted for their normal tissue
components, a hierarchical clustering of all subtracted
cancer samples was performed and presented as a heat-
map in Figure 2A. The overall pattern shows that the
samples are fairly heterogeneous with respect to their
signatures, but one major cluster (containing 54 of the
116 PCa samples, cluster 1 in Figure 2A) was separated
from the other samples by increased values for the ERG-
fusion, Embryonic Stem Cell (ESC) and MYC-positive
(MYC+) gene sets (average gene set values for this clus-
ter compared to other samples are shown in Figure 2B).
Although these three gene sets generally showed in-
creased values in samples from this cluster, the values
were not always increased at the same time. Typically,
two out of the three gene set values were increased in a
single sample. Among these three gene sets, the ESC
and MYC + sets correlated with each other (r = 0.64), but
neither correlated with the ERG-fusion set (r = -0.1 and
r = -0.2 for ESC and MYC + respectively). Additionally,
we also observed increased values for the PTEN- and
Proliferation gene sets, and depletion of the PRC2, Mes-
enchyme, RAS and Cytokine gene sets, however, these
enrichments and depletions were weaker and less con-
sistent across the samples in cluster 1. All 54 samples
except one in the identified cluster were assigned with
bad prognosis (p < 0.25). Interestingly, most of these
samples (n = 38) have low Gleason scores of 6 and 7,
despite being assigned with bad prognosis. Increased
values of gene set scores related to bad prognoses sub-
types were also observed in a substantial number of
samples with Gleason score 6 and 7 in the additional
validation dataset (Additional file 1: Text S1). The com-
bination of low Gleason score with bad prognosis may
indicate that high gene set values of ERG-fusion, MYC +
and ESC serve as early markers for a more dangerous
PCa subtype.
To validate the ERG-fusion, MYC + and ESC gene set
enrichments in our study, two recently published inde-
pendent gene sets for ESC and MYC were used (ESC-
New [18] and MYC_New [25]). Average GSEA scores
for these gene sets from the normal samples were also
subtracted for the new gene sets. The study containing
the MYC_New gene set also included additional gene
sets for Polycomb (PRC_New) and ES core pluripotency
factors (Core_New) which were also included in the val-
idation (Figure 2). Good correlations between the new
and existing gene set scores over all PCa samples were
observed (r = 0.62 and r = 0.88 for ESC/ESC_New and
MYC+/MYC_New, respectively), despite poor overlap of
genes both from the new and the existing gene sets (only28 of 189 for ESC and 18 of 355 for MYC). This clearly
indicates that GSEA calculated gene set scores are quite
robust with respect to the selection of genes in the sig-
nature, and highlights the benefit of using gene sets ra-
ther than individual genes for molecular characterization
of PCa. The PRC_New gene set scores were reduced in
the samples from the dominant cluster (cluster 1), which
was in accordance with the observed depletion in the exist-
ing PRC2 gene set scores (r = 0.75 for PRC2/PRC_New,
196 of 451 genes overlap).
To further validate the significance of the individual
gene sets (ERG-fusion, ESC, ESC_New, MYC and MYC_
New) in separating PCa samples with poor and good
prognosis, we compared the individual gene set scores for
these five signatures between the following sample sets: i)
The 54 cancer samples with bad prognosis from cluster 1
and highlighted in Figure 2, ii) The 21 cancer samples ini-
tially assigned with good prognosis (p < 0.25, Table 1A)
and iii) The 40 normal samples. The ESC, MYC + and
MYC_New show strongly elevated gene set scores over
the 54 samples with bad prognosis, compared to the good
prognosis and normal samples (Figure 1E), while the ele-
vation of ESC_New and ERG_fusion gene set scores are
less pronounced.
In addition to the dominant cluster 1, two smaller clus-
ters (2; purple, and 3; pink, Figure 2) with samples sharing
elevated scores of certain gene sets were also observed.
One of these clusters (cluster 2) contained samples par-
ticularly enriched for the Cytokine gene set. The majority
of samples (12 out of 18) in this cluster where categorized
with either Gleason 8 or 9, and the Cytokine gene set gen-
erally showed increased values in samples with higher
Gleason scores (Additional file 1: Figure S4). The other
small cluster (cluster 3) contained samples showing spe-
cific depletion in the Mesenchyme and ProNeural gene set
scores. Most samples in this cluster (4 out of 6) were from
the same patient, indicating that this patient may have a
less common type of PCa. The general similarity in signa-
tures among PCa samples from the same patient was also
evident in the hierarchical clusters, where 45 samples
shared a cluster neighbor with a sample from the same pa-
tient (only 5 samples would be expected to have this prop-
erty by chance). Finally, the low influence of tissue
composition on the sample clustering underlines the effect
of the subtraction procedure in limiting the tissue hetero-
geneity effect.
Discussion
Detection of PCa molecular subtypes revealing the prog-
nosis at an early stage of cancer development would be
helpful in stratifying patients to personalized treatment.
New prognostic models independent of Gleason grading
is the ultimate goal for adding new prognostic tools into
the clinic. In this study, we used fresh frozen prostatectomy
AB
Figure 2 Hierarchical clustering of signatures for all PCa samples reveal one dominating cluster (cluster 1, green) with low Gleason
scores, classified with poor prognosis profiles, and enriched for ERG-fusion, ESC and MYC + gene sets. Signature scores after subtraction
of the average normal signature were used for the clustering. A) Heatmap of signatures based on GSEA scores for the 15 gene sets in 116 cancer
samples. The additional bars show meta-data for each sample, from left to right: 1) Samples assigned with poor prognosis (red), good prognosis
(green) and unclassified (grey) at a p-value threshold of 0.25; 2) Percentage cancer tissue, 3) Gleason score, Gleason 6-7 (yellow), Gleason 8-9
(brown); 4) Whether a sample clusters with an adjacent sample from the same patient, yes (dark blue), no (white),5) Interesting clusters found in
the heatmap, see main text for details. Two of the most important gene sets were validated by four related gene sets from recent studies, where
the ESC_New, MYC_New and PRC_New gene set values correlated well with the previous ESC, MYC + and PRC2 gene set scores. Note that these
four gene sets were not used for the hierarchical clustering, and are thus independent validations. B) Average gene set values over all samples in
cluster 1, and compared to the average over all other cancer samples, emphasizing the characteristics for cluster 1.
Rye et al. BMC Medical Genomics 2014, 7:50 Page 9 of 12
http://www.biomedcentral.com/1755-8794/7/50
Rye et al. BMC Medical Genomics 2014, 7:50 Page 10 of 12
http://www.biomedcentral.com/1755-8794/7/50tissue of high molecular quality [17] thoroughly evaluated
by histopathology to validate previous and assess new mo-
lecular subtypes using microarray gene technology.
The histopathological evaluation of tissue composition
(amount of cancer and normal benign structures of
stromal and epithelial cells) in our fresh frozen sample
material enabled us to investigate the effect of sample
composition on PCa subtyping. By subtraction of an
average normal signature, we achieved an improved
classification of PCa samples. Still, a substantial number
of samples could not be assigned to any of the categor-
ies. This could be due to samples containing subtype
characteristics not captured by the gene sets used here,
or that an even more specific subtraction method has to
be used. However, the results clearly underline the im-
portance of accounting for tissue heterogeneity in the
analyses. Important information may be hidden and lost
because the variation due to tissue composition hetero-
geneity overshadows the biological variation of interest,
and this is also valid for analyses of other molecular
properties than the transcriptome. The identification of
PCa samples with good prognosis signatures are par-
ticularly challenging due to the molecular similarities
between these cancer subtypes and normal samples. A
consequence of this may be that cancers with poor
prognosis characteristics are assigned with good prog-
nosis because of high normal tissue content in the
sample.
PCa often has a multi-nodal character, being present
at separated and presumably independent foci in the
prostate. Some studies suggest that multifocal PCa most
likely has a monoclonal origin [40], making within pa-
tient variation between PCa samples less than the inter-
patient variation, even when samples are taken from
different foci. In our study, with many samples taken
from the same patient, we observe considerably higher
signature variability between than within patients, even
when the samples from the same patient have different
Gleason scores. This supports the hypothesis of a mono-
clonal origin, but is in contrast to a previous study target-
ing multi-nodality where the presence of i.e. gene fusions
was reported to vary in different foci. However, or study
was designed to obtain tissue of different Gleason grades,
and no specific focus was put on multi-nodality. In this
setting, samples taken from different foci in each patient
consistently showed similarities.
When subtracting the average normal signature from
the PCa samples, hierarchical clustering revealed a par-
ticular dominant cluster representing enrichments in the
ERG-fusion, ESC and MYC + gene sets. In our data, the
scores for these three gene sets were markedly higher in
samples of poor prognosis compared cancers with good
prognosis and normal samples, which should make them
able to discriminate between the categories. Additionally,the gene set scores for ESC and MYC +were validated
by recent gene sets for ESC and MYC from independent
studies. Genes from the additional ESC and MYC gene-
sets overlapped poorly with genes from the ESC and
MYC + gene-sets in Markert et al. [3], however the gene
set scores were highly correlated. This corroborates the
robustness of using gene sets related to specific proper-
ties or cell functions rather than individual genes for
classification and characterization. A substantial number
of PCa samples (38 of 116) assigned with poor clinical
prognosis had a low Gleason score (6 or 7) and consist-
ently showed high scores for these three gene sets. This
indicates that the features of these cancer samples are
quite common in PCa. Additionally, there were consist-
ent signatures from samples taken from the same patient
independent of different Gleason scores. ERG-fusion,
ESC and MYC + gene sets are thus interesting due to the
robustness to sample variability within the same patient,
their evidence at early stage PCa and the ability to predict
clinical poor prognosis.
In Markert et al. [3], there was a special focus on the
bad prognostic signature enriched for the ESC, PTEN-
and P53- signatures, while enrichment for ERG-fusion
was characteristic for an intermediate prognosis. Though
we observe some enrichment of the PTEN- gene set, we
find that both the PTEN- and the P53- gene sets are
more enriched in samples with Gleason score 8 and 9,
indicating that they are later events in PCa progression
[28]. Similar to Markert et al. [3], we also observe an en-
richment of the Mesenchyme and Cytokine gene sets in
normal samples and cancers with good prognosis. How-
ever, these gene sets are also enriched in cancers with Glea-
son score 8 and 9, thus making them too ambiguous for
early stage PCa assessment (Additional file 1: Figure S4). It
should also be noted that the P53- gene set only contain
four genes, of which only two are present in our micro-
array data, so scores for this gene set may lack robustness.
There are two important limitations in our study which
need to be mentioned. First, our data currently lack
follow-up information with respect to recurrence and pa-
tient survival. This means that the assessment of good and
poor prognosis in our study relies on follow-up data on
patient survival time from Markert et al. [3]. Follow up in-
formation from the additional validation dataset showed
recurrence in 13 of 29 patients assigned with a bad prog-
nosis signature together with a Gleason score of 6 or 7,
however, these numbers could not be compared to recur-
rence measures for samples assigned with good prognosis
due to insufficient data (Additional file 1: Text S1).
However, for early localized PCa with low Gleason
scores, follow up data may be of limited value, since a
successful radical prostatectomy likely prevents recur-
rence, regardless of whether the removed tumor contained
a potentially dangerous subtype or not. Nevertheless, the
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were clearly reproducible in the signatures calculated on
low Gleason samples in our data, as well as on the valid-
ation data, and are thus used as an indication of poten-
tially dangerous molecular characteristics which can be
identified at an early stage. To fully answer the question of
whether these tumors are more likely to become lethal if
they remain in the patient, tissue biopsies sampled from
tumors over time is necessary, but such samples are cur-
rently not readily available. In addition, our study adds
value by analyzing the signatures in the context of tissue
heterogeneity and intra-patient variability, both important
in a clinical perspective. Second, prostate tumors classified
with Gleason score 6 are generally not surgically removed,
so samples with Gleason score 6 are all taken from PCa
tissue which also harbored tumors with higher Gleason
score (most often a Gleason score of 7). We generally as-
sume that poor prognosis signatures in these samples are
indicative of an “early version” of the tumor with higher
Gleason. However, we also acknowledge the possibility
that the Gleason 6 samples may be exposed to a field effect
from the higher Gleason tumor, resulting in signatures re-
sembling poorer prognosis. However, the prevalent pres-
ence of poor prognosis signatures in samples from Gleason
6 patients in the additional validation set argues against
this.
Conclusions
We have validated gene expression signatures used for
identification of prognostic PCa subtypes in a new patient
cohort from standardized tissue material of high molecu-
lar quality. Our data provide new information on a sub-
type of cancer samples enriched for gene sets related to
ERG-fusion, ESC and MYC + indicating poor prognosis
on an early stage of PCa development (low Gleason score).
The identified signatures seem to be common for PCa,
consistent within the same patient and have the potential
to give important information on dangerous PCa beyond
Gleason grading. These PCa subtypes are promising in a
clinical setting for treatment planning and as inclusion cri-
teria for active surveillance programs. For the future, we
need to validate the signatures further in larger patient co-
horts and develop more sophisticated regimes to correct
for tissue composition heterogeneity.
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